The endoscopic retrograde cholangiopancreatography (ERCP) devices market sales is expected to reach US$ 1.5 billion in 2022 and US$ 2.8 billion by 2032 as a result of an increase in cancer incidence worldwide. The market for endoscopic retrograde cholangiopancreatography (ERCP) equipment is anticipated to develop at a compound annual growth rate (CAGR) of 6.2% between 2022 and …